Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Net Income: 2009-2025

Historic Net Income for China Pharma Holdings (CPHI) over the last 17 years, with Sep 2025 value amounting to -$651,482.

  • China Pharma Holdings' Net Income rose 41.72% to -$651,482 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.2 million, marking a year-over-year increase of 32.76%. This contributed to the annual value of -$4.7 million for FY2024, which is 53.84% down from last year.
  • China Pharma Holdings' Net Income amounted to -$651,482 in Q3 2025, which was down 23.30% from -$528,367 recorded in Q2 2025.
  • In the past 5 years, China Pharma Holdings' Net Income ranged from a high of -$475,976 in Q1 2023 and a low of -$1.4 million during Q2 2024.
  • For the 3-year period, China Pharma Holdings' Net Income averaged around -$889,146, with its median value being -$785,572 (2025).
  • Its Net Income has fluctuated over the past 5 years, first tumbled by 6,418.56% in 2021, then skyrocketed by 63.26% in 2025.
  • China Pharma Holdings' Net Income (Quarterly) stood at -$980,719 in 2021, then fell by 28.90% to -$1.3 million in 2022, then rose by 2.53% to -$1.2 million in 2023, then grew by 0.63% to -$1.2 million in 2024, then surged by 41.72% to -$651,482 in 2025.
  • Its Net Income stands at -$651,482 for Q3 2025, versus -$528,367 for Q2 2025 and -$785,572 for Q1 2025.